Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 11, 2009

Persistent Upgrades LIMS Application to Include Tissue Data for UC-Davis

  • Persistent Systems has partnered with the University of California, Davis to develop a data-management system for preclinical scientists. The tool called caELMIR 2 (electronic laboratory management information resource) will be based on the company’s caBIG® LIMS application.

    The updated version of caELMIR is integrated with caTissue, caBIG’s tissue-bank repository tool, for biospecimen inventory, tracking, and basic annotation. This caELMIR-caTissue integration reportedly enables scientists to store and access both preclinical data and tissue repository data, allowing them to find and procure tissues from previous experiments.

    Traditionally scientists have had to use specially designed databases to store the various data sets. The database was ineffective, however, when data collected did not fit in it. Additionally, such silo systems had synchronization issues, creating incomprehensible data.

    caELMIR 2 reportedly helps address these issues. It allows investigators to manage every aspect of preclinical studies, including tracking experimental tissue data and utilization, managing experiments, and handling the multitude of data types recorded for given experiments.

    The integration fully re-uses existing common data elements (CDE), ensuring semantic interoperability and retaining existing metadata information of all re-used CDEs to ensure seamless data exchange over the caGrid.



GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »